Merck Investors Win Class Cert. In 2 Suits Over Vytorin

Law360, New York (September 26, 2012, 6:23 PM EDT) -- A New Jersey federal judge on Tuesday granted class certification in a pair of related suits brought by investors claiming drugmaker Merck & Co. and subsidiary Schering-Plough hid test results that showed their anti-cholesterol drug Vytorin did not work.

U.S. District Judge Dennis M. Cavanaugh said the plaintiffs, large institutional investors, had put forward enough evidence that the alleged concealment harmed their shareholders a whole.

“Plaintiffs have sufficiently demonstrated the existence of a causal relationship between the announcement of unexpected news and an immediate response in...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

MANSON v. SCHERING-PLOUGH CORPORATION et al


Case Number

2:08-cv-00397

Court

New Jersey

Nature of Suit

Securities/Commodities

Judge

Esther Salas

Date Filed

January 18, 2008


Case Title

GENESEE COUNTY EMPLOYEES' RETIREMENT SYSTEM v. MERCK & CO., INC. et al


Case Number

2:08-cv-02177

Court

New Jersey

Nature of Suit

Securities/Commodities

Judge

Esther Salas

Date Filed

May 5, 2008

Law Firms

Companies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.